Article: Studies of SARS virus vaccines.

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleStudies of SARS virus vaccines.
AuthorsZheng, BJ1
Du, LY1
Zhao, GY1
Lin, YP1
Sui, HY1
Chan, C1
Ma, S1
Guan, Y1
Yuen, KY1
Issue Date2008
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
CitationHong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy Of Medicine, 2008, v. 14 Suppl 4, p. 39-43 [How to Cite?]
Abstract1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.
ISSN1024-2708
2011 SCImago Journal Rankings: 0.054
DC Field
Value
dc.contributor.authorZheng, BJ
dc.contributor.authorDu, LY
dc.contributor.authorZhao, GY
dc.contributor.authorLin, YP
dc.contributor.authorSui, HY
dc.contributor.authorChan, C
dc.contributor.authorMa, S
dc.contributor.authorGuan, Y
dc.contributor.authorYuen, KY
dc.date.accessioned2012-08-08T08:51:18Z
dc.date.available2012-08-08T08:51:18Z
dc.date.issued2008
dc.description.abstract1. Intranasal vaccination using inactivated SARS coronavirus (SARS-CoV) vaccine with adjuvant can induce strong systemic (serum immunoglobulin [Ig] G) and respiratory tract local (tracheal-lung wash fluid IgA) antibody responses with neutralising activity. 2. RBD-Fc (protein-based vaccine) is able to induce effective neutralising antibodies able to provide protection from SARS-CoV infection in animal models. 3. A single dose of RBD-rAAV vaccination can induce adequate neutralising antibody against SARS-CoV infection. 4. Additional doses of vaccine increased the production of neutralising antibody 5-fold compared with a single dose. 5. RBD-rAAV vaccination provoked a prolonged antibody response with continually increasing levels of neutralising activity. 6. Intranasal vaccination with RBD-rAAV induced local IgA and systemic IgG neutralising antibodies and specific T-cell responses, able to protect against SARS-CoV infection in animal models. 7. When compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide boost induced similar levels of Th1 and neutralising antibody responses that protected vaccinated mice from subsequent SARS-CoV challenges,but stronger Th2 and CTL responses. 8. Overall, our findings suggest that the inactivated vaccine, RBD-Fc and RBD-rAAV, can be further developed into effective and safe vaccines against SARS and that intranasal vaccination may be the preferred route of administration.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationHong Kong Medical Journal = Xianggang Yi Xue Za Zhi / Hong Kong Academy Of Medicine, 2008, v. 14 Suppl 4, p. 39-43 [How to Cite?]
dc.identifier.epage43
dc.identifier.hkuros156461
dc.identifier.issn1024-2708
2011 SCImago Journal Rankings: 0.054
dc.identifier.pmid18708674
dc.identifier.scopuseid_2-s2.0-70449859520
dc.identifier.spage39
dc.identifier.urihttp://hdl.handle.net/10722/157565
dc.identifier.volume14 Suppl 4
dc.languageeng
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
dc.publisher.placeHong Kong
dc.relation.ispartofHong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Medical Association.
dc.subject.meshAdministration, Intranasal
dc.subject.meshAnimals
dc.subject.meshCommunicable Disease Control
dc.subject.meshDisease Models, Animal
dc.subject.meshDisease Outbreaks - Prevention & Control
dc.subject.meshFemale
dc.subject.meshForecasting
dc.subject.meshHong Kong
dc.subject.meshHumans
dc.subject.meshInjections, Intramuscular
dc.subject.meshMale
dc.subject.meshMice
dc.subject.meshPredictive Value Of Tests
dc.subject.meshRisk Assessment
dc.subject.meshSars Virus - Immunology
dc.subject.meshSevere Acute Respiratory Syndrome - Epidemiology - Immunology - Prevention & Control
dc.subject.meshVaccination - Statistics & Numerical Data
dc.subject.meshVaccines, Inactivated - Administration & Dosage
dc.subject.meshViral Vaccines - Administration & Dosage - Immunology - Pharmacology
dc.titleStudies of SARS virus vaccines.
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong